BridgeBio is substantially improved its development of the novel therapy for ATTR-CM, employing the compound. Early trial information reveals potential improvements for individuals diagnosed by a serious disease. The effort highlights the company’s commitment to addressing unmet healthcare demands in the heart disease arena. Attruby: BridgeBio's